GlassScriptPhysician profile
Lydia Evans
NPI 1295758803
$7,433.17
in general payments reported to CMS, 2019-2025
25 companies · $1,721 in 2025
The $1,721 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $706 · 2021: $1,234 · 2022: $812 · 2023: $1,121 · 2024: $1,137 · 2025: $1,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,834 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,833.61 |
| Education | $145.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,085.76 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $1,027.76 | 2019-2025 | Absorica Ld, Winlevi, Blu-U |
| Lilly USA, LLC | $808.04 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Abbvie INC. | $596.19 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $576.42 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $534.63 | 2019-2025 | Nemluvio, Aklief |
| Merz North America, INC. | $522.28 | 2019-2024 | |
| Amgen INC. | $438.91 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $418.07 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $312.05 | 2019-2025 | |
| Ucb, INC. | $234.79 | 2024-2025 | Bimzelx |
| Incyte Corporation | $174.73 | 2021-2023 | |
| Vyne Pharmaceuticals INC. | $162.82 | 2020-2021 | |
| Allergan, INC. | $157.31 | 2019-2022 | |
| Journey Medical Corporation | $64.81 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $57.40 | 2024-2025 | Vyjuvek |
| Dusa Pharmaceuticals, INC. | $54.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.56 | 2019-2020 | |
| Celgene Corporation | $34.53 | 2019 | |
| Arcutis Biotherapeutics, INC. | $32.24 | 2023-2025 | Zoryve |
| Botanix Sb INC | $26.30 | 2025 | Sofdra |
| Biofrontera INC. | $19.77 | 2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Chiesi USA, INC. | $18.73 | 2024 | Filsuvez |
| Prugen, INC. Pharmaceuticals | $14.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.90 | 2024 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.